What CZ Vaccines does

CZ Vaccines S.A.U. is a Spanish biopharmaceutical company and wholly-owned subsidiary of the Zendal Group, headquartered in O Porriño, Pontevedra (Spain). The company operates a dual business model: as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end vaccine and biological product development and manufacturing services to multinational pharmaceutical companies, laboratories, governments, and biotech start-ups/spin-offs; and as a producer of its own proprietary veterinary vaccine portfolio spanning brucellosis, bluetongue, clostridial, Aujeszky's disease, pasteurellosis, paratuberculosis, rabies, and swine erysipela indications.

The company's technical platform spans multiple vaccine modalities — conventional vaccines, genetically engineered live attenuated vaccines, subunit/recombinant protein vaccines, and DNA vaccines — for both human and animal health applications. CZ Vaccines claims to be the first producer in mycobacteria, reflecting specialized expertise in this technically demanding category. Manufacturing infrastructure includes BSL-2 viral and bacterial vaccine capabilities, bioreactors up to 6,000L (both single-use and stainless steel), four filling machines at 6,000-24,000 vials/hour, freeze-dryers handling up to 200,000 vials per run, and downstream processing including chromatography, centrifugation, ultrafiltration, and tangential flow filtration.

Operations span three manufacturing sites: O Porriño (Spain, headquarters), León (Spain), and Paredes de Coura (Portugal), with cGMP-certified production and a global commercial reach across 65+ countries. The company is privately held (Sociedad Anónima Unipersonal, NIF A-36.201.259), employs 101-250 people, and has 30+ years of operating history. Revenue is generated through project-based CDMO contracts and commercial sales of proprietary veterinary vaccines distributed via regional distributors and direct government supply relationships, with pricing conducted on a quote-based, per-project negotiation basis typical of contract biomanufacturing.

Name

CZ Vaccines

Legal name

CZ Vaccines S.A.U.

Website

https://czvaccines.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

CZ Vaccines is a Spanish CDMO and veterinary vaccine manufacturer serving multinational pharma, governments, and biotech start-ups. Operating three Iberian facilities with cGMP infrastructure, it produces animal health vaccines and provides end-to-end contract development and manufacturing services.

Ownership category

akta.pro rank

Headquarters

HQ city

Pontevedra

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Development and manufacturing services for third parties including multinational companies, laboratories, and governments worldwide. Services span from R&D through commercial manufacturing, including semi-finished products and finished products ready for commercialization.
2. Own Vaccine Portfolio: Sale of proprietary animal health vaccine products including brucellosis, bluetongue, clostridial diseases, and other veterinary vaccines.
3. COVID-19 Collaboration Projects: Collaborative research and manufacturing projects for COVID-19 solutions utilizing the company's R&D and manufacturing capabilities.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

CZ Vaccines develops and manufactures vaccines and biological products, operating as a Contract Development and Manufacturing Organization (CDMO) for multinational pharmaceutical companies, laboratories, and governments worldwide. The company provides end-to-end services spanning R&D, cGMP manufacturing, fill-finish, lyophilization, and regulatory support for viral and bacterial vaccines up to BSL-2. It also markets its own proprietary portfolio of veterinary vaccines, diagnostics, and adjuvants for animal health.

Product overview

CZ Vaccines is a biopharmaceutical company specializing in the development and manufacturing of biological products and vaccines for both human and animal health. The company's product portfolio consists primarily of veterinary vaccines and diagnostics, organized into three main categories: animal health vaccines (including brucellosis vaccines like CZV REV-1, RB-51 CZV, B19 CZV, OCUREV; bluetongue vaccines like BLUEVAC BTV; clostridial vaccines like CUBOLAC; and vaccines for diseases such as Aujeszky, pasteurellosis, paratuberculosis, rabies, and swine erysipela), diagnostic products (including avian and bovine tuberculin PPD tests, and ROSE BENGAL screening tests), and pharmaceutical products (including vaccine adjuvants like ADJUVAL and iron supplements like HIPPIRON). In addition to its own product portfolio, CZ Vaccines operates as a CDMO (Contract Development and Manufacturing Organization) providing end-to-end development and manufacturing services for third parties, including human health vaccines (bacterial and viral vaccines up to BSL-2 with aseptic processing, lyophilization, and fill-finish capabilities) and animal health products. The company is part of the Zendal group and maintains manufacturing facilities in Spain and Portugal.

Differentiator

Problem solved

Functional benefit

Brands

• Preventing with Experts: Digital tool on pharmacoeconomics with expert testimonials and marketing applications for veterinarians.

Products and services

• ALGONTEX Inactivated vaccine against contagious agalactia in sheep and goats caused by Mycoplasma agalactiae.
• AUSCHKY Active immunization against Aujeszky's disease (pseudorabies) with IgE marker allowing differentiation between vaccinated and naturally infected animals.
• BLUEVAC BTV Active immunization of cattle and sheep against bluetongue virus serotypes 1, 4 and 8.
• CZV REV-1 Active immunization against Brucella melitensis in sheep and goats.
• ADJUVAL - AL(OH)3 Vaccine adjuvant with very high protein-adsorbing capacity.
• HIPPIRON Treatment of iron deficiency in racing and sporting horses.
• ROSE BENGAL Screening test for serological diagnosis of infections caused by Brucella in ruminants.
• CZV AVIAN TUBERCULIN PPD Diagnosis of bovine tuberculosis by means of the comparative test with simultaneous injection of Avian PPD and Bovine PPD tuberculin.
• CZV BOVINE TUBERCULIN PPD Diagnosis of bovine tuberculosis by means of the single intradermal test or comparative test.
• IBERITEX Active immunization against swine Erysipela caused by Erysipelothrix rhusiopathiae.
• B19 CZV OCULAR Active immunization of cattle (young animals aged 4-8 months) against Brucella abortus via ocular route.
• RB-51 CZV Active immunization against Brucella abortus in cattle.
• OCUREV Active immunization against Brucella melitensis in sheep and goats via ocular route.
• GUDAIR Inactivated vaccine against paratuberculosis (Johne's disease) caused by Mycobacterium avium paratuberculosis.
• ETADEX Inactivated rabies vaccine (Flury strain) for active immunization of dogs and cats.
• DILPHES Active immunization against pasteurellosis in sheep, goats and cattle.
• SILIRUM Active immunization of cattle to reduce shedders, development of lesions and bacterial load due to Mycobacterium avium ssp. paratuberculosis.
• CUBOLAC Immunization of cattle, sheep and goats against blackleg, black disease, braxy, malignant edema and enterotoxemias caused by Clostridium species.
• COLIDEX-C Inactivated vaccine against neonatal and post-weaning diarrhea in piglets caused by Escherichia coli and Clostridium perfringens type C.
• B19 CZV Active immunization of cattle (young animals aged 4-8 months) against Brucella abortus.
• Human Health CDMO Services End-to-end contract development and manufacturing services for human viral and bacterial vaccines up to BSL-2, including aseptic processing, lyophilization, fill-finish, regulatory support and tech transfer for multinational pharmaceutical companies, laboratories and governments.
• Animal Health CDMO Services Contract development and manufacturing services for animal health vaccines and pharmacological products, providing scale-up, fill-finish, and regulatory support to third-party developers and manufacturers.

Quantifiable outcome

• Manufacturing capacity in Spain and Portugal serving clients in 65+ countries

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• VISAVET (Centro de Vigilancia Sanitaria Veterinaria)minorStrategic or Co-development PartnerConsortium partner in the 3G diagnoTB project (RTC-2016-4746-2) for third-generation bovine tuberculosis diagnostics. VISAVET is responsible for biological evaluation and field validation.
• ISCIII (Instituto de Salud Carlos III)minorStrategic or Co-development PartnerConsortium partner in the 3G diagnoTB project responsible for immunoproteomic characterization of bovine tuberculosis diagnostic components.
• Universidad de ZaragozaminorStrategic or Co-development PartnerAcademic partner in the Baciloterapia bladder cancer treatment project, collaborating on the clinical translation of MTBVAC vaccine developed by the university.
• Zendal GroupcoreOthersCZ Vaccines belongs to Zendal, a biopharmaceutical group comprising seven companies focused on research, development, manufacturing, and marketing of high added-value health products.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Bavarian Nordic: Specialty vaccine developer and contract manufacturer with live viral vaccine expertise and BSL-2/3 capabilities, overlapping with CZ Vaccines' viral vaccine platform and CDMO services for human and animal health.
• Seqirus: Specialty vaccine manufacturer (CSL subsidiary) with in-house fill-finish and BSL-2 viral vaccine capacity, comparable in platform scope and customer types to CZ Vaccines' human-health CDMO work.

Broad incumbents

• Catalent: Major global CDMO with extensive biologics fill-finish, lyophilization and vaccine capabilities, competing with CZ Vaccines for outsourcing contracts across both human and animal health.
• Zoetis: Largest global animal health company with a deep proprietary vaccine portfolio across livestock and companion animals, a broad incumbent that competes with CZ Vaccines' veterinary product franchise.
• Lonza Group: Global large-scale biologics and vaccine CDMO with mammalian and microbial suites, competing with CZ Vaccines for large pharmaceutical contract manufacturing and process development work.
• Boehringer Ingelheim BioXcellence: Animal-health-focused biologics CDMO within Boehringer Ingelheim, providing contract manufacturing of veterinary vaccines and biopharmaceuticals comparable to CZ Vaccines' animal-health CDMO offering.

Direct peers

• Vetter Pharma: Specialist CDMO focused on aseptic fill-finish of biologics and vaccines including lyophilization, closely comparable to CZ Vaccines' fill & finish capabilities (4 lines, 6,000–24,000 vials/hour; 2 freeze dryers, up to 200,000 vials per run).
• HIPRA: Spanish-headquartered animal health pharmaceutical and vaccine manufacturer with proprietary veterinary products and CDMO services, a direct regional competitor with overlapping product categories and customer base.
• IDT Biologika: Germany-headquartered vaccine and biologics CDMO with mammalian and microbial capacity and fill-finish operations, directly competing with CZ Vaccines in contract vaccine development and manufacturing for human and animal health customers.
• Eurofins CDMO: Mid-sized European CDMO offering biologics process development, GMP manufacturing and QC, competing for similar-scale CDMO contracts as CZ Vaccines across Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/czvaccines

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CZ Vaccines